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Background: To support public health policy, information on the burden of disease is essential. In recent years, the
Disability-Adjusted Life Year (DALY) has emerged as the most important summary measure of public health. DALYs
quantify the number of healthy life years lost due to morbidity and mortality, and thereby facilitate the comparison
of the relative impact of diseases and risk factors and the monitoring of public health over time.
Discussion: Evidence on the disease burden in Belgium, expressed as DALYs, is available from international and
national efforts. Non-communicable diseases and injuries dominate the overall disease burden, while dietary risks,
tobacco smoking, and high body-mass index are the major risk factors for ill health. Notwithstanding these efforts,
if DALYs were to be used for guiding health policy, a more systematic approach is required. By integrating DALYs in
the current data generating systems, comparable estimates, rooted in recent local data, can be produced. This
might however be hampered by several restrictions, such as limited harmonization, timeliness, inclusiveness and
accessibility of current databases.
Summary: Routine quantification of disease burden in terms of DALYs would provide a significant added value
to evidence-based public health policy in Belgium, although some hurdles need to be cleared.
Keywords: Belgium, Disease burden, Disability-adjusted life years, Health policyBackground
The main goal of public health policy is to promote,
enhance and protect the population’s health. This requires
information on the health status of the population, often
referred to as the “burden of disease”. More than just the
presence/absence of specific diseases and conditions, dis-
ease burden encompasses a comprehensive quantification
of the physical and psychosocial health impact of diseases,
conditions, and risk factors [1].
Evidence on the disease burden is important for decision-
making processes within the health sector. In order to
make relevant decisions and set appropriate priorities, pol-
icy makers need to be informed about the size of health* Correspondence: brecht.devleesschauwer@UGent.be
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article, unless otherwise stated.problems in the population, the groups that are particu-
larly at risk, and the trends in the state of health over time.
In addition, an accurate estimate of the population’s health
status can be used for determining the expected health care
use and is vital for prioritizing effective interventions and
evaluating their impact and cost-effectiveness (e.g., by inte-
grating them in generalized cost-effectiveness analyses [2]).
The disease burden of the population can be described
by a variety of indicators. Indeed, public health is a multi-
factorial phenomenon with many facets and different ways
to measure it. Typical indicators of population health are
life expectancy, cause-specific mortality rates, numbers of
new and existing cases of specific diseases (i.e., incidence
and prevalence), perceived health, the occurrence of phys-
ical and mental limitations and disability, but also more
indirect measures, such as absenteeism, incapacity of
work, and the use of medical facilities and the associatedd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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facet of public health, i.e., either mortality or morbidity.
Summarizing public health in terms of mortality-based
indicators, such as life expectancy, dates from the time
when only reliable data for mortality existed. In many
countries, however, one has been confronted with an epi-
demiological transition of public health problems. The im-
portance of early mortality due to plagues and famines has
been replaced by chronic, non-communicable diseases,
while communicable diseases remain a real threat, causing
a “double burden” [3]. Cardiovascular diseases and cancers
have replaced infectious diseases as the main causes of
death. However, these diseases are also associated with an
important morbidity component, due to the life prolong-
ing effect of continuously improving medical practice [4].
Moreover, not only an extended life expectancy per se is
aimed for, living these extra years in good health has be-
come just as important [5]. As a result, current health
policy requires a global overview of public health, one
that combines morbidity and mortality and takes account
of health-related quality of life (HRQoL; [6]).
Given the importance of combining morbidity and
mortality, the last few decades have seen important
methodological advances in so-called summary measures
of population health (SMPH; [7]). By and large, SMPHs
may be divided into two broad families, namely health
expectancies and health gaps. Metrics of each family
combine morbidity and mortality into a single figure.
Health expectancy-based metrics, such as Disability-Free
Life Expectancy (DFLE), Healthy Life Years (HLY), and
Disability-Adjusted Life Expectancy (DALE), translate these
indicators into a health-adjusted life expectancy; health gap
metrics, such as the Disability-Adjusted Life Year (DALY),
translate these indicators into a number of life years lost
due to bad health and mortality.
Driven by the influential Global Burden of Disease
(GBD) projects initiated in the early 1990s, the DALY has
become the dominant SMPH [8-12]. In the remainder of
this debate, we will therefore outline the composition of
the DALY metric and its data needs. Next, we will sum-
marize existing DALY estimates for Belgium, providing an
overview of the current state-of-knowledge on the burden
of disease in Belgium. We will conclude by discussing the
added value and potential hurdles of routine DALY calcu-
lation for Belgian public health policy.
Discussion
Disability-adjusted life years
What are DALYs?
The DALY concept was developed for the World Bank’s
World Health Report 1993, Investing in Health [13]. To
estimate the global burden of disease, the World Bank
required a metric that allowed comparing health acrosscountries. Equity issues were therefore central concepts
in the development of DALYs [14,15].
DALYs measure the health gap from a life lived in per-
fect health, and quantify this health gap as the number
of potentially healthy life years lost due to morbidity,
disability and mortality. A disease burden of 100 DALYs
per 1000 people-year would thus imply a loss of 100
healthy life years per 1000 people per year. Diseases or
risk factors accounting for more DALYs thus have a
higher public health impact.
The DALY is composed of a morbidity and a mortality
component [14-16]. Morbidity is quantified in terms of
Years Lived with Disability (YLDs), the loss of healthy
life years from living in a less-than-perfect health state.
YLDs for a given health state are calculated by multiply-
ing the number of incident cases with the duration and
the disability weight of the health state. An alternative,
prevalence-based version of the YLD, introduced in the
GDB 2010 study, is defined as the number of prevalent
cases multiplied with the disability weight [1]. In both
versions, the disability weight is a crucial component,
reflecting the relative reduction in HRQoL on a scale from
zero (perfect health) to one (worst possible health state).
Mortality is quantified in terms of Years of Life Lost (YLLs),
the loss of healthy life years from dying before a predefined
life expectancy. YLLs are calculated by multiplying the
number of deaths with the residual life expectancy at the
age of death. The standard DALY formulas may be exten-
ded by applying age weighting or time discounting [14-16].
These so-called social weighting functions are however not
accepted by all authors [17,18]. As a result, the use of age
weighting and time discounting is declining, even in the
most recent updates of the GBD [1,12].
Data needs
It is obvious that the quality of the DALY estimate dir-
ectly depends on the quality of the input data [19]. To
obtain the most accurate DALY estimate, it is therefore
necessary to have reliable incidence (or prevalence) and
mortality data. Ideally, one would like to have data from
a nationally representative system that continuously moni-
tors the occurrence of all disorders in the population,
based on a set of clearly defined diagnostic criteria. As
such registration does not exist, one must resort to what
exists. In Belgium, several large and important data gener-
ating systems are in place:
– The national health surveys (performed in 1997,
2001, 2004, 2008 and 2013; https://his.wiv-isp.be/)
– The national cancer registry (http://www.
kankerregister.org/)
– The 40 national reference centers and 16 national
reference laboratories for human microbiology
(https://nrchm.wiv-isp.be/; [20])
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microbiology laboratories (https://www.wiv-isp.
be/epidemio/epien/index8.htm; [21])
– The mandatory reporting of specific agents.
Taking into account the level of under-reporting and
under-ascertainment, these data sources can provide valu-
able information on the incidences of the included diseases
and risk factors.
The direct use of healthcare providers’ data is difficult
in Belgium, given the stringent privacy rules in place [22].
However, certain data are made available as Minimal
Clinical, Hospital, Nursing, and Psychiatric Data. These
data sources are merely focused on the financial im-
pact of diseases, and thus provide valuable information
for estimating the direct health-related costs [23]. The
announced intention to update the disease classification
system to ICD-10-BE (International Classification of
Disease, 10th Revision – Belgian Modification) in the do-
main Medical Data of the Minimal Hospital Data [24],
might prove valuable for health impact assessment studies,
given that non-aggregated data are made available.
In addition to the national data collection systems,
there are various data collection mechanisms at the re-
gional level. However, the routine use of these data
sources to generate nationally relevant burden estimates
might be problematic, due to the lack of harmonization
between databases and data collection procedures in the
different Belgian regions. Moreover, the diseases that are
being registered are different between regions, making
the availability of the routine data incomplete for a part
of the country.
When local data are not readily available, one may
resort to international databases or data from neighboring
countries. However, Vanthomme et al. [25] report that lack
of timeliness can be an important constraint to the use of
three major health databases (i.e., WHO-HFA, OECD, and
EUROSTAT). Also, when extrapolating data from neigh-
boring countries, one assumes that the Belgian health
situation is similar to that of its neighbors.
The lack of data harmonization in the Belgian system is
mainly because of the absence of a unique national system
of health data collection. There are several individual ini-
tiatives from public and private institutions, but commu-
nication between these different actors is poor. Several
registries for the same disease exist (e.g. diabetes registry),
but the stage from which the patient is included into a
certain registry is sometimes poorly defined. Moreover,
the codes used to define the disease, the identification of
the patients and the follow-up period are different be-
tween registries making them impossible to merge. The
split of health competences between federal state, regions
and communities is one of the explanations of this dispar-
ate system of health data collection.Finally, several diseases are not well registered in
Belgium, such as foodborne diseases (FBD) and especially
diseases caused by chemicals. The impact of FBD on pub-
lic health is difficult to evaluate and these diseases are not
prioritized in Belgium, creating a vicious circle of lacking
data [26].
The burden of disease in Belgium
Estimates on the burden of disease in Belgium are
available from both international and national efforts.
However, if disease burden were to support policy, a more
systematic approach is required, generating comparable
estimates rooted in recent, local data.
International efforts
To date, the two most comprehensive sources of disease
burden estimates for Belgium are the most recent GBD
studies conducted by the World Health Organization
(WHO) and the Institute for Health Metrics and Evaluation
(IHME). The results of WHO’s so-called Global Health
Estimates (GHE) are available online as a series of spread
sheet documents (http://www.who.int/healthinfo/global_
burden_disease/estimates/en/index2.html). The results
of IHME’s GBD 2010 study are available online via inter-
active data visualization tools (http://www.healthdata.org/
gbd/data-visualizations), via detailed databases [27] and via
a summary report [28,29].
According to WHO GHE, the total disease burden in
Belgium in 2012 was 29.468 DALYs per 100,000, of which
41% was due to morbidity and 59% due to mortality. Non-
communicable diseases attributed 85%, injuries 10%,
and the group of communicable, maternal, perinatal
and nutritional conditions the remaining 5%. The group
of non-communicable diseases was dominated by malig-
nant neoplasms and cardiovascular diseases (each con-
tributing ~20%), followed by mental, neurological and
musculoskeletal disorders (each contributing ~10%). Falls,
road traffic accidents and self-harm were each responsible
for 20-30% of the entire injury burden. Lower respiratory
infections dominated the communicable disease burden
(37% of communicable, maternal, perinatal and nutritional
conditions). Table 1 shows the top 20 causes of DALYs,
YLDs and YLLs for Belgium in 2012 according to WHO,
and their change in ranking since 2000. There has been a
significant increase in the importance of Alzheimer’s dis-
ease and falls, while the relative importance of road traffic
accidents and breast cancer has decreased.
The GBD 2010 study showed a broadly similar picture
[28,29], which is not surprising as WHO GHE adopted
most GBD 2010 YLD estimates and used the same mortal-
ity data for calculating YLLs. Nevertheless, there are slight
differences in methods, data sources and groupings of
causes [12]. Table 2 shows the top 20 causes of DALYs,
YLDs and YLLs for Belgium in 2010 according to IHME,
Table 1 Top 20 causes of Disability-Adjusted Life Years (DALY), Years Lived with Disability (YLD) and Years of Life Lost
(YLL) in Belgium, 2012, according to WHO global health estimates
Rank DALY YLD YLL
1 Ischaemic heart disease [=] Back and neck pain [=] Ischaemic heart disease [=]
2 Other circulatory diseases [=] Unipolar depressive disorders [=] Trachea, bronchus, lung cancers [=]
3 Trachea, bronchus, lung cancers [=] Falls [=] Other circulatory diseases [=]
4 Back and neck pain [+1] Other musculoskeletal disorders [=] Stroke [=]
5 Alzheimer’s disease and other
dementias
[+6] Alcohol use disorders [=] Other malignant neoplasms [+1]
6 Chronic obstructive pulmonary disease [=] Alzheimer’s disease and other
dementias
[=] Chronic obstructive pulmonary disease [+1]
7 Unipolar depressive disorders [=] Chronic obstructive pulmonary disease [=] Alzheimer’s disease and other
dementias
[+6]
8 Stroke [−4] Ischaemic heart disease [=] Self-harm [−3]
9 Falls [+3] Anxiety disorders [=] Colon and rectum cancers [=]
10 Other malignant neoplasms [−1] Migraine [=] Lower respiratory infections [+1]
11 Alcohol use disorders [+2] Osteoarthritis [=] Breast cancer [−1]
12 Self-harm [−2] Road injury [=] Other digestive diseases [=]
13 Other musculoskeletal disorders [+2] Asthma [=] Road injury [−5]
14 Colon and rectum cancers [+2] Schizophrenia [=] Cirrhosis of the liver [=]
15 Road injury [−7] Other circulatory diseases [+1] Other unintentional injuries [+4]
16 Other digestive diseases [+2] Drug use disorders [−1] Pancreas cancer [+1]
17 Breast cancer [−3] Bipolar disorder [=] Other respiratory diseases [−2]
18 Lower respiratory infections [−1] Other unintentional injuries [=] Other infectious diseases [+2]
19 Other unintentional injuries [+1] Rheumatoid arthritis [=] Lymphomas, multiple myeloma [−1]
20 Anxiety disorders [+2] Stroke [=] Falls [+3]
The change in rank since 2000 is given between brackets, with ‘+’ indicating an increase in rank, ‘–’ a decrease in rank, and ‘=’ a status quo.
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period, the most striking increases are again those of the
neurological, mental and musculoskeletal disorders.
GBD 2010 further provides estimates on the contribution
of risk factors to the disease burden. In the general popu-
lation, the three most important risk factors were dietary
risks (e.g., high sodium, low fruits and vegetables), tobacco
smoking, and high body-mass index. Second-hand smoke
exposure was a leading risk factor for children under 5,
while alcohol use was the major risk factor for adults
aged 15–49.
In addition to these global consortia, the European
Centre for Disease Control (ECDC) is currently under-
taking a burden of communicable disease study in Europe
[30]. In a pilot study, the burden of six infectious diseases
was quantified, though only YLDs could be calculated
(Figure 1; [31]).
National efforts
So far, only few national efforts have been undertaken to
study the disease burden in Belgium. The DALY as
policy-relevant measure for Belgium was first described
by Baert et al. [32], in the Flemish Health IndicatorReport 1998. To demonstrate the use of DALYs, the
authors initiated a pilot study in which they quantified the
Flemish disease burden for reference year 1997 [33]. The
list of included diseases and risk factors was inspired by
the Dutch national disease burden study [34]. DALYs were
calculated based on the Flemish life expectancy table,
using non-uniform age weighting and a 3% time discount
rate, making these estimates incomparable with the afore-
mentioned GBD estimates.
More recently, the Flemish Institute for Technology
and Development (VITO) assessed the burden of envi-
ronmental risk factors in Flanders, commissioned by the
Flemish Environment Agency (VMM; [35]). Figure 2 sum-
marizes their findings, showing air particulate matter to
be the most important environmental risk factor.
In addition to these larger studies, several researchers
estimated the burden of specific health conditions in
Belgium. However, as DALY calculation methods differed
across studies, care should be taken in comparing the
resulting estimates. Stassen et al. [36] estimated the mean
burden due to transportation noise in Flanders in 2004 to
be 20,517 DALYs, or 342 DALYs per 100,000. Dhondt
et al. [37] quantified the burden of road traffic accidents in
Table 2 Top 20 causes of Disability-Adjusted Life Years (DALY), Years Lived with Disability (YLD) and Years of Life Lost
(YLL) in Belgium, 2010, according to IHME GBD 2010
Rank DALY YLD YLL
1 Ischaemic heart disease [=] Low back pain [=] Ischaemic heart disease [=]
2 Low back pain [=] Major depressive disorder [=] Lung cancer [+1]
3 Stroke [=] Falls [+2] Stroke [−1]
4 Lung cancer [=] Neck pain [−1] Self-harm [+1]
5 COPD [=] Other musculoskeletal [−1] COPD [+1]
6 Falls [+3] COPD [=] Colorectal cancer [+1]
7 Major depressive disorder [=] Alzheimer’s disease [+5] Road injury [−3]
8 Alzheimer’s disease [+8] Diabetes [+2] Lower respiratory infections [+2]
9 Self-harm [−1] Ischaemic heart disease [=] Breast cancer [−1]
10 Road injury [−4] Migraine [−2] Alzheimer’s disease [+6]
11 Neck pain [−1] Anxiety disorders [−4] Other cardio & circulatory [−2]
12 Other musculoskeletal [+2] Drug use disorders [−1] Cirrhosis [−1]
13 Diabetes [−2] Osteoarthritis [+1] Pancreatic cancer [+4]
14 Colorectal cancer [−1] Road injury [−1] Diabetes [−1]
15 Other cardio & circulatory [=] Alcohol use disorders [=] Falls [+5]
16 Breast cancer [−4] Asthma [+1] Prostate cancer [+3]
17 Lower respiratory infections [=] Schizophrenia [+2] Brain cancer [+1]
18 Migraine [+1] Other hearing loss [−2] Leukaemia [+3]
19 Anxiety disorders [+1] Dysthymia [+2] Stomach cancer [−7]
20 Cirrhosis [−2] Bipolar disorder [=] Chronic kidney disease [+2]
The change in rank since 1990 is given between brackets, with ‘+’ indicating an increase in rank, ‘–’ a decrease in rank, and ‘=’ a status quo.
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DALYs, or 1030 DALYs per 100,000. In absolute numbers,
car users contributed most DALYs, whereas per travelled
km, motorcyclists contributed most. Henrard et al. [38]
estimated the burden of haemophilia in Belgium in 2011 at
145 DALYs (95% credible interval [CI]: 90–222), or 1.3
DALYs per 100,000 (95% CI: 0.8–2.0).
Summary
By quantifying the total disease burden and the contri-
bution of different diseases and risk factors, DALYs are aFigure 1 Years lived with disability calculated in a pilot study on commuhighly valuable measure to set priorities for public health
research and policy. Furthermore, if data allow, DALYs
may be calculated for different socioeconomic groups or
geographic regions, allowing for a more detailed perspec-
tive on public health. By regularly updating the DALY esti-
mates based on the best available data, trends in public
health may be monitored over time, and the impact of
macro-level policies may be evaluated. As a result, DALYs
may be important tools to support policy that aims to
improve general population health and reduce health in-
equalities [39]. For this reason, the IHME is initiatingnicable diseases in Europe, based on data from 2003 to 2005 [30,31].
Figure 2 Disability-adjusted life years for environmental risk factors in Flanders, based on data from 1998 to 2011 [35]. Note that the
x-axis uses a logarithmic scale.
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wide [40]. The WHO Regional Office for Europe is collab-
orating with IHME to facilitate national burden of disease
study in the European region and enhance consistency of
burden estimates.
Current DALY estimates for Belgium highlight the im-
portance of non-communicable diseases and injuries.
However, several constraints can be identified that might
hamper the policy relevance of the currently available esti-
mates. First, most DALY estimations remained academic
exercises, with little or no direct knowledge transfer to the
concerned policy instances. Indirect knowledge transfer
may have occurred by referring to existing burden esti-
mates in research proposals, but the effect is difficult to
assess. Second, while global estimates provide a broad
overview of the health status in Belgium, it remains a
question to what extent these estimates are grounded in
the best available local data. There may also be issues
related to timeliness and ownership of these global esti-
mates. Third, while national research groups did more
efforts to apply local data sources, there appears to be
little consistency in the applied DALY calculation method-
ology. As a result, the individual DALY studies cannot be
combined to obtain a comparable evaluation of Belgians’
health. Researchers are therefore advised to calculateDALYs under different social weighting scenarios, and
to present at least relative DALY estimates (e.g., DALYs
per 100,000 people-year).
To overcome these limitations and generate a system-
atic and truly comparable measurement of Belgians’
health, DALYs should be integrated in the different offi-
cial data collection systems. This is already the case in
the Netherlands and Australia, where DALYs are guiding
health policy since the past 10–20 years [34,41]. In
Belgium, various large and important data generation sys-
tems are in place that could provide the data required for
calculating DALYs. However, there are also some potential
hurdles, such as a lack of timeliness of certain databases, a
restricted access to hospital data for routine use, a limited
harmonization between regional databases, and the ab-
sence of certain diseases from the major databases. Given
the increasing importance of neurological, mental and
musculoskeletal disorders, the absence of comprehen-
sive, harmonized databases for these disorders is par-
ticularly striking. Nevertheless, we believe that the
routine quantification of disease burden in terms of
DALYs would provide a significant added value to public
health policy in Belgium and should be integrated in all
national mechanisms for the translation of evidence
into policy.
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